Removing barriers to clinical trial participation for underserved groups is an essential part of addressing health inequalities. Getting there, however, is easier said than done.
The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials, recommends sponsors develop and submit a race and ethnicity diversity plan early in clinical development.
Speakers at a recent Patients as Partners webinar on the document welcomed its publication, and explained how community and collaboration were the keys to turning theory into practice.
